XML 90 R64.htm IDEA: XBRL DOCUMENT
v3.25.1

Discontinued operations (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2024
Discontinued operations |
Schedule of profit (loss) for the year and cash flows from discontinued operations | a. The results and cash flows from discontinued operations for the year ended December 31, 2022, are shown below:
| Oxiteno |  |  | Extrafarma |  |  | Eliminations (*) |  |  | Ultrapar |  |  | 12/31/2022 |
Net revenue from sales and services | 2,039,287 |  |  | 1,235,487 |  |  | (7,241 | ) |  | ‐ |  |  | 3,267,533 |
Cost of products and services sold | (1,580,000 | ) |  | (912,310 | ) |  | 7,241 |  |  | ‐ |  |  | (2,485,069 | )
Gross profit | 459,287 |  |  | 323,177 |  |  | ‐ |  |  | ‐ |  |  | 782,464 |
Selling, marketing and administrative | (201,365 | ) |  | (438,601 | ) |  | ‐ |  |  | ‐ |  |  | (639,966 | )
Other operating income (expenses), net | 10,736 |  |  | (5,951 | ) |  | ‐ |  |  | 241,325 |  |  | 246,110 |
Operating income (loss) | 268,658 |  |  | (121,375 | ) |  | ‐ |  |  | 241,325 |  |  | 388,608 |
Share of profit (loss) of subsidiaries, joint ventures and associates | (231 | ) |  | ‐ |  |  | ‐ |  |  | ‐ |  |  | (231 | )
Income (loss) before financial result and income and social contribution taxes | 268,427 |  |  | (121,375 | ) |  | ‐ |  |  | 241,325 |  |  | 388,377 |
Financial result, net | 23,153 |  |  | (25,059 | ) |  | 54,431 |  |  | ‐ |  |  | 52,525 |
Income (loss) before income and social contribution taxes | 291,580 |  |  | (146,434 | ) |  | 54,431 |  |  | 241,325 |  |  | 440,902 |
Income and social contribution taxes | (16,924 | ) |  | 20,826 |  |  | (18,507 | ) |  | (202,895 | ) |  | (217,500 | )
Net effect of cessation of depreciation (i) | 51,372 |  |  | 27,084 |  |  | ‐ |  |  | ‐ |  |  | 78,456 |
Net income (loss) for the year | 326,028 |  |  | (98,524 | ) |  | 35,924 |  |  | 38,430 |  |  | 301,858 |
(*) | Elimination between continuing and discontinued operations related to the intercompany loan between Ultrapar International and Oxiteno.
(i) | As of January 1, 2022, the depreciation and amortization of assets classified as held for sale ceased, in compliance with item 25 of IFRS 5.
| Oxiteno |  |  | Extrafarma |  |  | Eliminations |  |  | 12/31/2022 |
Net cash (consumed) provided by operating activities | (81,558 | ) |  | (68,370 | ) |  | 180,478 |  |  | 30,550 |
Net cash (consumed) provided by investing activities | 1,011,736 |  |  | (25,323 | ) |  | (1,206,603 | ) |  | (220,190 | )
Net cash (consumed) provided by financing activities | (1,245,754 | ) |  | 40,585 |  |  | 1,026,144 |  |  | (179,025 | )
Effect of exchange rate variation on cash and cash equivalents in foreign currency | (19,316 | ) |  | ‐ |  |  | ‐ |  |  | (19,316 | )
Increase (decrease) in cash and cash equivalents | (334,892 | ) |  | (53,108 | ) |  | 19 |  |  | (387,981 | )

X
- Definition The disclosure of the analysis of the single amount of discontinued operations. [Refer: Discontinued operations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 5 -IssueDate 2024-01-01 -Paragraph 33 -Subparagraph b -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_b&doctype=Standard -URIDate 2024-03-27 + Details
Name: | ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration